Pertuza 420 mg/14 ml (IV Infusion)
14 ml vial: ৳ 70,000.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Pertuzumab |
| Company | Incepta pharmaceuticals ltd |
Indications
- HER2-positive metastatic breast cancer treatment
- Neoadjuvant treatment of breast cancer
- Adjuvant treatment of breast cancer
Pharmacology
- Monoclonal antibody
- Inhibits HER2 receptor
- Role in cancer cell growth
Dosage & Administration
- Intravenous infusion only
- Initial dose: 840mg
- Subsequent dose: 420mg
- HER2 testing required
- Specific administration schedules for different treatments
Interaction
- No drug-drug interactions observed
Contraindications
- Hypersensitivity to pertuzumab or its excipients
Side Effects
- Common adverse reactions in metastatic breast cancer treatment
- Common adverse reactions in neoadjuvant treatment of breast cancer
- Common adverse reactions in adjuvant treatment of breast cancer
Pregnancy & Lactation
- Pregnancy status verification
- No information on presence in human milk
- Effects on breastfed infants and milk production
Precautions & Warnings
- Infusion-related reactions monitoring
- Hypersensitivity reactions/anaphylaxis monitoring
Therapeutic Class
- Targeted Cancer Therapy
Storage Conditions
- Refrigeration at 2°C to 8°C
- Protection from light